Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 18:S0091-6749(25)00649-9.
doi: 10.1016/j.jaci.2025.06.007. Online ahead of print.

T-cell and autoantibody profiling for primary immune regulatory disorders

Affiliations

T-cell and autoantibody profiling for primary immune regulatory disorders

Emily M Harris et al. J Allergy Clin Immunol. .

Abstract

Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD). Increased CD4+CXCR5+PD1+ circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.

Objective: We sought to develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

Methods: We recruited 74 controls and 101 pediatric patients with PIRD with autoimmunity. Flow cytometry was used to measure CD4+CXCR5+ T cells expressing the chemokine receptors CXCR3 and/or CCR6. IgG and IgA autoantibodies were quantified in 56 patients and 20 controls using a microarray of 1616 full-length, conformationally intact protein antigens. The cTfh cell percentages exceeding 12% of CD4+ T cells were considered increased, as previously published, and the 97.5th percentile in the controls was the upper limit of normal for CD4+CXCR5+ T cells expressing CXCR3 and/or CCR6 and autoantibody intensity and number.

Results: We found that 27.7% of patients had increased percentages of CD4+CXCR5+PD1+ cTfh cells, and 42.5% had increased percentages of CD4+CXCR5+ cells expressing CXCR3 and/or CCR6. Patients had significantly more diverse IgG and IgA autoantibodies than controls, and 37.5% of patients had increased numbers of high-titer autoantibodies. Integrating measurements of cTfh cells, CD4+CXCR5+ T cells with CXCR3 and/or CCR6, and numbers of high-titer autoantibodies had 71.4% sensitivity (95% CI 58.5%-81.6%) and 85.0% specificity (95% CI 64.0%-94.8%) for patients with PIRD compared with controls.

Conclusions: Integrating CD4+ T-cell phenotyping and total burden of autoantibodies can enhance detection of autoimmunity in PIRD.

Keywords: Autoimmunity; T follicular helper cells; autoantibodies; primary immune regulatory disorders.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement This work was supported by the National Institutes of Health (T32HL007574 to E.M.H.; T32AI007512 to S.C., B.L., D.P.H.v.K., and J.C.; K12HD052896 to D.P.H.v.K.; and R01DK130465 to J.C.), Immune Deficiency Foundation (to B.L.), Thrasher Research Fund (to E.M.H.), Immune Deficiency Foundation (to E.M.H.), Lin Family Fund (to J.C.), and Perkin Fund (to J.C.). The Children’s Rare Disease Cohort initiative funded the whole-exome sequencing of study participants. Sources of funding had no role in the study design or execution, data interpretation, or writing of the manuscript. Disclosure of potential conflict of interest: D. P. Hoytema van Konijnenburg is a consultant for Adivo Associates and Guidepoint Global. L. A. Henderson received salary support from the Childhood Arthritis and Rheumatology Research Alliance, investigator-initiated research grants from Bristol Myers Squibb, and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. T. K. Ohsumi was an employee of BeBiopharma. J. M. Peyper is an employee of Sengenics. R. F. Grace receives research funding from Novartis, Sobi, and Agios and is a consultant for Agios, Sobi, and Sanofi. The rest of the authors declare that they have no relevant conflicts of interest.

Update of

Similar articles

Cited by

LinkOut - more resources